Igniting Drug Discovery
Monday, August 26, 4pm-5:30pm PT
Where: Online
In the latter half of the 20th century, the number of those suffering with dementia rose dramatically. It’s the early innings of the 21st century, and yet there are no cures for this debilitating disease. We can do precision strikes targeting enemies in war, we can have fancy smartphones as powerful as rockets, and yet where we are in drug discovery seems to pale in comparison. There’s some headway in cancer treatments with antibody drug conjugates and new ways to enhance cell therapies.
It does seem we are on the cusp of some major drug breakthroughs, despite the entire drug development process being long, complicated and costly. But in a post-CRISPR and generative AI world, there are innovative applications, tools and components that are advancing and igniting drug discovery. Some of the new trends include 3D cell culture, assay development, synthetic biology, patient-central trials and advanced manufacturing to robust microbe databases.
Join us to learn about new trends. But to also hear from innovative startups in Tokyo creating the building blocks to the actual drugs themselves. These startups have been identified by the Tokyo government as among the promising ones to watch. They are part of Hypergrowth Tokyo, a late-stage scaling program.
(Image source: ICR)
REGISTRATION !
AGENDA
4pm-4:30pm - A conversation around the new trends in drug development. Moderator: Bambi Francisco Roizen; Panelists: Rosanna Zhang, VP ACROBiosystems
4:30pm-5:30pm: Presenting Tokyo late-stage companies. Akira Onoda (CEO of NGENIESS), Junu Kim (CEO of Auxiliart), Yuki Suzuki (CEO of bitBiome), Norio Kaneko (CEO of Flying Cell); Panelists: Jenny Rooke (Managing Director, Genoa Ventures)
